Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 86Breast Neoplasms 15Neoplasms 6Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Salivary Gland Neoplasms 2Prostate Adenocarcinoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leiomyoma 2Hodgkin Disease 2Uveal Melanoma 1Uterine Neoplasms 1Urogenital Neoplasms 1Skin Neoplasms 1Skin Diseases 1Salivary Gland Neoplasm Duct 1Recurrence 1Rare Diseases 1Prostatic Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1PSA Level Greater Than Two 1Obesity, Morbid 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Melanoma 1Lymphoma, Mantle-Cell 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hormone Sensitive Prostate Cancer × Leuprolide × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡